Blue Skies: Merck Looks For Chronic Pain Candidates In Australia
This article was originally published in PharmAsia News
In a deal described as “out of the blue” by Australian biotech Bionomics, Merck has acquired an option to license a small molecule for up to $172 million in fees and milestones as part of a two-year research program focused on chronic pain treatments.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.